Skip to content
Screener

Exelixis EXEL Short-Term Investments

Short-Term Investments at other companies

Pfizer logo
PfizerPFE
$11.37B-28.4%
Kura Oncology logo
Kura OncologyKURA
$541.74M-10.7%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$222.01M+40.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$552M-16.7%
Gilead Sciences logo
Gilead SciencesGILD
$0-100%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$255.9M+32.8%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemJune 30, 2026December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents$281,448$482,488
Marketable securities557,937576,603
Trade receivables, net322,213286,916
Inventory28,72921,686
Prepaid expenses and other current assets60,49575,596
Total current assets1,250,8221,443,289

Item 1. Financial Statements.

FAQ

What is Exelixis's short-term investments?
Exelixis (EXEL) reported short-term investments of $557.94M in Q2 2026.
How has Exelixis's short-term investments changed year-over-year?
Exelixis's short-term investments decreased by 11.0% year-over-year, from $626.67M to $557.94M.
What is the long-term trend for Exelixis's short-term investments?
Over 5 years (2020 to 2025), Exelixis's short-term investments has grown at a -8.3% compound annual growth rate (CAGR), from $887.32M to $576.6M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Ask your AI about Exelixis's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude